Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

Abstract

BackgroundHCV virus (HCV) is a significant global problem with wide-ranging socio-economic impacts. Because of the high morbidity and mortality associated with end-stage liver disease, cirrhosis, and hepatocellular carcinoma (HCC), the economic burden of HCV infection is substantial.ObjectivesThis study aimed to estimate the direct medical care costs of chronic HCV infection.Patients and MethodsFor this cross-sectional study, 365 courses of HCV treatment were extracted from medical records of 284 patients being referred to Tehran HCV clinic, a clinical clinic of Baqiyatallah Research Center for Gastroenterology and Liver diseases, from 2005 to 2010. All the patients had been diagnosed with HCV. Direct medical care costs for each course of HCV treatment have been calculated based on Purchasing Power Parity Dollar (PPP$).ResultsAverage direct medical costs for the courses treated with conventional interferon plus ribavirin (INF-RBV) were 4,403 PPP$, and 20,010 PPP$ for peg-interferon plus ribavirin (PEG-RBV) courses. There was an increase of the direct costs in both courses of treatment to achieve Sustain Viral Response (SVR). The costs amounted to 10,072 PPP$ in (INF-RBV) treatment and 34,035 PPP$ in (PEG-RBV). The significant difference between the costs of these two courses of treatment is attributable to high cost of Peg-interferon. This indicates that the medication costs are the dominant costs.ConclusionsAccording to the results, total direct medical costs for HCV patients in Iran exceeded 12 billion PPP$ in (INF-RBV) treatment and 55 billion PPP$ in (PEG-RBV).

Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea

“…Actually, the dominant cost in patients with CHC or CC is related to the treatment of HCV, as suggested in a study from the Middle East, which stated that most of the direct medical costs for patients receiving HCV treatment were attributable to the prescription of interferon or pegylated interferon. [14] However, patients with DC or HCC, irrespective of prior antiviral therapy for HCV, required management and monitoring of complications. Thus, “treatment and surgery fees” and “examination fees” as well as “medication and dispensing fees” would be the dominant costs in patients with DC and HCC.…”

Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials

“…Furthermore, whereas chronic HCV infection increases morbidity and mortality, sustained eradication of HCV (sustained virological response; SVR) improves patients' survival, PRO scores, and reduces the risk of liver complications and the HCV‐related economic burden …”

Hepatocellular carcinoma in Asia: Prevention strategy and planning

“…Combination therapy decreases the risk of HCC in patients with HCV-related cirrhosis, even without complete biochemical and virological clearing [60] . The current treatments for HCV are combination therapy of pegylated interferon with ribavirin [114][115][116][117] .…”